UNSPSC 51286702: Brodimoprim

This classification denotes a dihydrofolate reductase inhibitor with the molecular formula C13H15BrN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1YC7T6LLI, chemically known as 2,4-pyrimidinediamine, 5-((4-bromo-3,5-dimethoxyphenyl)methyl)- but more generally known as brodimoprim, which bears US NIH Compound Identifier 68760. European Medicines Agency schedules Brodimoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05898MIG.

UNSPSC 51286702 Brodimoprim is a Commodity code that in recent state and local procurement activity encompasses pharmaceutical and medical supply procurement far broader than the nominal code name suggests — including naloxone, emergency medical consumables, generic pharmaceuticals, and over-the-counter products sourced through both direct purchase and cooperative purchasing vehicles. State and local issuing bodies pursuing this code include county health departments, city fire and rescue divisions, state health and human services agencies, and multi-state cooperative purchasing alliances. The work involves specification of National Drug Code numbers, negotiation of pricing models with wholesalers and manufacturers, compliance with FDA and cGMP standards, and delivery logistics to medical facilities and emergency response divisions.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (noting a date inconsistency in the source); the City of Tampa's Purchasing Department posted IFB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division at an estimated contract value of $700,000, with a March 13, 2026 deadline and a certified Small Local Business Enterprise set-aside offering a 5 percent bid discount capped at $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to work through authorized wholesalers and comply with FDA and Drug Supply Chain Security Act requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling emerging interest in alternative distribution models outside traditional pharmacy benefit manager and group purchasing organization channels.